Business briefs: Allergan, Incyte, Medtronic, Aetna
August 21, 2013
5:16 pm
Allergan asks FDA to reconsider Restatis generics requirements, Incyte’s Jakafi could be pancreatic cancer nemesis, Medtronic says its strategy is at the heart of where healthcare is going and Aetna’s app alliance makes health local and personal.
Business briefs: Abbott, IMS Health, Boehringer, plus healthcare reform
August 19, 2013
6:09 pm
Abbott’s Depakote lawsuits roll on; IMS buys mobile health firm’s assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.
Business briefs: Eisai, Merck, plus another ACA delay
August 13, 2013
6:11 pm
Eisai lobbies to push back Belviq’s patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back
Business briefs: Healthcare reform, J&J, Lilly, Quest
July 18, 2013
6:08 pm
The healthcare reform information campaign continues; J&J settles a shareholder lawsuit; Eli Lilly freezes company salaries; and Quest dumps cancer med royalty rights.
The White House released its proposed budget for the 2014 fiscal year this morning, and while it gives a modest boost to Health and Human Services, it also seeks to extract more cost savings from pharmas.
Full steam ahead for Obamacare, but gridlock isn’t going anywhere
President Obama has cemented his greatest legislative achievement, the Affordable Care Act, but the status quo should prove anything but boring, with implementation of the law sure to mean more political fireworks
Voting with their wallets, pharmas say no thanks to change
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
Docs’ presidential preferences follow practice type
Solo practitioners favor Mitt Romney over Barack Obama by a two-to-one ratio, a survey finds, suggesting that changes in reimbursement driven by Obamacare are driving physicians’ presidential preferences.
An analysis by PricewaterhouseCoopers projects Affordable Care Act-related revenue gains of only $15 billion and tabulates a net loss of $140 billion for pharmas under the law
Court upholds Obamacare but limits Medicaid expansion
The Supreme Court upheld the individual mandate, leaving the Affordable Care Act on solid ground and ensuring higher sales volumes for drug companies after 2014, but limited the law’s expansion of Medicaid, which will curb the number of newly insured and dampen those sales increases.